Search - tctmd.com

Displaying 641 - 660 of 683

Sort: Relevancy | Date

News Industry News

Non-adherence to dual antiplatelet therapy following percutaneous coronary intervention results in higher rates of ischemic and bleeding events

November 08, 2011

News Industry News

Data from REMEDEE Trial Featuring OrbusNeich's ComboTM Dual Therapy Stent to Be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011

November 01, 2011

News Industry News

PLC Systems Receives FDA Approval to Commence Pivotal Study of RenalGuard in the U.S.

October 14, 2011

News Daily News

In-hospital Bleeding after Primary PCI Increases Long-term Mortality

October 10, 2011

News Daily News

HORIZONS-AMI: CKD Patients Fare Poorly Regardless of Stent Type, Antithrombotic Regimen

Leah Lawrence

September 29, 2011

News Daily News

BARC: New Bleeding Definitions Aim to Standardize Trial Endpoints

L.A. McKeown

June 17, 2011

News Industry News

PLC Ramps Up for U.S. Clinical Trial of RenalGuard®

June 02, 2011

News Conference News

Therapies Take on In-Stent Restenosis with Mixed Results

Caitlin E. Cox

April 15, 2011

News Conference News

Induced Diuresis with Automated Hydration Therapy Reduces CIN

April 05, 2011

News Conference News

For Bifurcations, 1 Stent Just as Good as 2 Out to 5 Years

Jason Kahn

April 03, 2011

Video

» Conference Wrap-Up

Welcome to TCT 2025

October 25, 2025

Video

» Interview

ACC 2025 Conference Wrap-Up

April 2, 2025

Partner Content

Cerebral Embolic Protection – A Next Generation Approach for Contemporary TAVR Practice

November 14, 2024

Video

» Conference Wrap-Up

TCT 2024 Day 4 Wrap-Up

October 30, 2024

Video

» Conference Wrap-Up

TCT 2024 Day 2 Wrap-Up

October 28, 2024

Video

» Conference Wrap-Up

EuroPCR 2024 Wrap-Up

May 20, 2024

Video

» Conference Wrap-Up

AHA 2023 Wrap-Up

November 15, 2023

Partner Content

Antiplatelet Decision Making in High-Risk PCI

November 15, 2023

Video

» Topical Discussion

Antiplatelet Decision Making in High-Risk PCI

November 14, 2023

Video

» Interview

A Look Ahead to TCT 2022 in Boston

September 2, 2022

Advertisement

Non-adherence to dual antiplatelet therapy following percutaneous coronary intervention results in higher rates of ischemic and bleeding events

Data from REMEDEE Trial Featuring OrbusNeich's ComboTM Dual Therapy Stent to Be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011

PLC Systems Receives FDA Approval to Commence Pivotal Study of RenalGuard in the U.S.

In-hospital Bleeding after Primary PCI Increases Long-term Mortality

HORIZONS-AMI: CKD Patients Fare Poorly Regardless of Stent Type, Antithrombotic Regimen

BARC: New Bleeding Definitions Aim to Standardize Trial Endpoints

PLC Ramps Up for U.S. Clinical Trial of RenalGuard®

Therapies Take on In-Stent Restenosis with Mixed Results

Induced Diuresis with Automated Hydration Therapy Reduces CIN

For Bifurcations, 1 Stent Just as Good as 2 Out to 5 Years

Welcome to TCT 2025

ACC 2025 Conference Wrap-Up

Cerebral Embolic Protection – A Next Generation Approach for Contemporary TAVR Practice

TCT 2024 Day 4 Wrap-Up

TCT 2024 Day 2 Wrap-Up

EuroPCR 2024 Wrap-Up

AHA 2023 Wrap-Up

Antiplatelet Decision Making in High-Risk PCI

Antiplatelet Decision Making in High-Risk PCI

A Look Ahead to TCT 2022 in Boston

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content